- Conditions
- Myeloproliferative Neoplasms
- Interventions
- INCA033989, Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Duarte, California • Palo Alto, California • Miami, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2233–2256
of 12,556
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Interventions
- Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Julio Barredo, MD
- Other
- Eligibility
- 16 Years to 39 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
- Interventions
- Patritumab deruxtecan, Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more
- Conditions
- Insulin-like Growth Factor-1 Deficiency
- Interventions
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- IMO-2055
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 9
- States / cities
- Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
- Conditions
- Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
- Interventions
- Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV Infections
- Interventions
- Mycophenolate mofetil, Amdoxovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 11 more
- Conditions
- Highly Sensitized Patients on Waiting List for Kidney Transplantation
- Interventions
- Inebilizumab, VIB4920, Inebilzumab+VIB4920
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- San Diego, California • Bethlehem, Pennsylvania
- Conditions
- Colon Cancer
- Interventions
- PDT with 5-ALA radiosensitization
- Drug
- Lead sponsor
- Edward Nelson
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Orange, California • New York, New York
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Recurrent Small Cell Lung Carcinoma, Refractory Small Cell Lung Carcinoma, Lung Cancer Stage IV, Large Cell Neuroendocrine Carcinoma, Neuroendocrine Tumors, Small Cell Lung Cancer Metastatic, Small-cell Lung Cancer
- Interventions
- Nivolumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- Ixabepilone, Trastuzumab, Carboplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 12
- States / cities
- Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2001
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
- Conditions
- Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
- Interventions
- INCB000928, ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 9 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
- Conditions
- Healthy
- Interventions
- PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Malignant Glioma
- Interventions
- MK-3475, MRI-guided laser ablation
- Biological · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes
- Interventions
- Dietary intervention
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
- Interventions
- Ofatumumab, Bendamustine
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 6
- States / cities
- Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
- Conditions
- Substance Use Disorders
- Interventions
- Core Training: FBS System Mapping and MTFS-I Installation, Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings
- Behavioral
- Lead sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Brentwood, New York • Buffalo, New York
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pazopanib, Abexinostat, Placebo
- Drug · Other
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • San Francisco, California + 10 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Venetoclax, Lenalidomide, Rituximab
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • Ann Arbor, Michigan • Columbus, Ohio + 1 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Survodutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 65 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Bimekizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Bexley, Ohio